RSA Institute
RSA Institute focuses on recurrent spontaneous abortion (RSA), reproductive medicine, and related research, academic exchange, technology development, professional cooperation, and international communication.
About RSA Institute
RSA Institute grew out of the international development activities of Beijing Xinjing Antai Medical Technology Services Co., Ltd. (北京新景安太医疗科技服务有限公司). It was established in the United States to support research, academic exchange, technology development, professional cooperation, and international outreach in recurrent spontaneous abortion and reproductive medicine.
RSA Institute was registered in 2011, with Fenglin Chen serving as Chief Executive Officer. From the beginning, its work combined research, professional exchange, technology development, and the international introduction of Antai’s medical technologies and patents.
Antai Hospital has focused mainly on clinical care and the application of related medical technologies, while RSA Institute has focused on research, academic development, professional cooperation, and international communication.
Institutional Profile
Historical Development
Globalization Planning and Strategy Discussion
Before the establishment of RSA Institute, shareholders of Beijing Xinjing Antai discussed the international development and globalization of the Antai brand. These discussions laid the foundation for the later establishment of RSA Institute and its international work.
November 9, 2011 — Registration and Establishment
On November 9, 2011, under authorization from Beijing Xinjing Antai Medical Technology Services Co., Ltd., Fenglin Chen established RSA Institute in the United States as part of the company’s international development.
Its purpose was to support research, academic exchange, technology development, and related work in recurrent spontaneous abortion and reproductive medicine.
2012–2013 — Team Growth and International Outreach
By 2012–2013, RSA Institute had developed a seven-member team: Jian Tong, Jing Wan, Xiaofan Wang, Xinglin Fan, Sophia H. Ma, Fenglin Chen, and Yinueryahefu Ma.
The group worked on introducing Antai’s medical technologies and patents to a wider international audience, including website development, Google search optimization, YouTube and Facebook outreach, and communication with medical institutions and professionals in related fields.
International Academic Exchange
RSA Institute and Beijing Xinjing Antai developed professional communication and academic exchange with specialists and visitors from the United States and other countries. These exchanges supported broader international cooperation in recurrent spontaneous abortion and reproductive medicine.
Early Office in Southern California
RSA Institute maintained an office in El Monte, California, where the team carried out research coordination, international outreach, website and media work, professional communication, and administrative activities.
2013 — Development in the United States
In 2013, RSA Institute continued to expand its activities in the United States. Its work included research planning, professional collaboration, international communication, and preparations for longer-term institutional development.
2014 — Continued Expansion
In 2014, RSA Institute continued to broaden its research and international activities, while developing plans for future facilities and long-term work in reproductive medicine and related biomedical fields.
Antai Land and Future Research Institute Plan
Antai Land was included in RSA Institute’s long-term development plan. The site was intended for the future construction of a research institute supporting scientific research, academic exchange, technology development, and related work in recurrent spontaneous abortion and reproductive medicine.
Long-Term Mission
RSA Institute continues to focus on recurrent spontaneous abortion, reproductive medicine, academic exchange, professional cooperation, and the development and international communication of related medical technologies.
Contact RSA Institute
Phone / WhatsApp: +1 949 886 2134 | WeChat: +86 139 1067 3491